CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.19 USD
+0.04 (3.48%)
Updated Sep 24, 2024 04:00 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for CytomX Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 101 | 53 | 70 | 100 | 57 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 101 | 53 | 70 | 100 | 57 |
Selling & Adminstrative & Depr. & Amort Expenses | 108 | 155 | 153 | 149 | 168 |
Income After Depreciation & Amortization | -6 | -101 | -84 | -49 | -111 |
Non-Operating Income | 10 | 2 | 0 | 2 | 8 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 3 | -99 | -84 | -47 | -103 |
Income Taxes | 4 | 0 | 0 | -14 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -1 | -99 | -84 | -33 | -102 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -1 | -99 | -84 | -33 | -102 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -12 | -99 | -81 | -46 | -111 |
Depreciation & Amortization (Cash Flow) | -5 | 2 | 3 | 2 | 0 |
Income After Depreciation & Amortization | -6 | -101 | -84 | -49 | -111 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 73.81 | 65.74 | 64.15 | 46.15 | 45.34 |
Diluted EPS Before Non-Recurring Items | -0.01 | -1.51 | -1.30 | -0.71 | -2.26 |
Diluted Net EPS (GAAP) | -0.01 | -1.51 | -1.30 | -0.71 | -2.26 |
Fiscal Year end for CytomX Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 25.12 | 41.46 | 26.61 | 26.38 | 24.72 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 25.12 | 41.46 | 26.61 | 26.38 | 24.72 |
SG&A, R&D, and Dept/Amort Expenses | 33.57 | 29.80 | 27.22 | 23.26 | 28.07 |
Income After SG&A, R&D, and Dept/Amort Expenses | -8.45 | 11.66 | -0.61 | 3.12 | -3.35 |
Non-Operating Income | 1.97 | 2.18 | 2.51 | 2.69 | 2.26 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -6.48 | 13.84 | 1.91 | 5.82 | -1.09 |
Income Taxes | 0.05 | 0.05 | 1.07 | 2.82 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -6.53 | 13.79 | 0.84 | 2.99 | -1.09 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -6.53 | 13.79 | 0.84 | 2.99 | -1.09 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 84.88 | 82.63 | 83.70 | 80.73 | 66.54 |
Diluted EPS Before Non-Recurring Items | -0.08 | 0.17 | 0.01 | 0.04 | -0.02 |
Diluted Net EPS (GAAP) | -0.08 | 0.17 | 0.02 | 0.04 | -0.02 |